Formulary

Name: Formulary
Brand: Formula Kino

Formulary is an AI-supported fund administration platform that combines managed fund administration services with software to improve data quality, operational workflows, and investor/LP reporting for private markets asset managers.

Website

01Competitive Landscape

Narrative analysis

- Direct competitors and differentiators - Formulary - Differentiation is presented as a fund administration approach that uses AI and automation to support workflows and emphasizes data reliability and client service. - Carta - Offers fund management and fund administration with a broader platform strategy and multiple add-ons (tax, valuations, forecasting, KYC, etc.). - SS&C - Competes on breadth, scale, and institutional coverage across accounting, reporting, and investor servicing. - Feature comparison: where Formulary may excel vs lag behind (evidence-limited) - Potential strengths (to validate) - Operational turnaround could be faster if processes are modernized - Improved client responsiveness if staffed and organized accordingly - A more consolidated system experience versus multi-tool legacy stacks - Potential gaps - Edge-case handling for complex structures - Depth of integration ecosystem compared with incumbents - Global coverage and specialist teams (tax, regulatory reporting across jurisdictions) - Pricing comparison: value proposition vs alternatives - Carta and SS&C are typically sales-led and quote-based; buyers report pricing complexity in the market. - Because Formulary doesn’t publish pricing, buyers should benchmark with competing quotes for similar fund structures and service levels. - Customer testimonials comparing Formulary to competitors - Public, independent comparisons were not found in accessible sources during this research pass. - Market share and adoption trends - No independent market share estimates were found in accessible sources for Formulary specifically. - Industry context: incumbents like SS&C are widely established in fund administration.

	Formulary (vendor website)	Carta Fund Administration	SS&C (Fund Administration)
Starting Price	Not publicly listed (quote-based likely)	Not transparently listed as a simple number; contact sales model with add-ons	Not publicly listed (enterprise/quote-based)
Typical buyers	Asset managers seeking an administration service that emphasizes AI-supported tooling and enhanced data controls	Managers wanting to consolidate within the Carta ecosystem and buy add-ons across fund management	Large and complex managers needing a scaled incumbent with broad coverage and long operating history
Key Strength	Vendor states a focus on data reliability, automation, and client service; these claims require validation	Broad platform footprint; add-on modules across fund operations	Scale, breadth, established processes, global capabilities
Key Weakness	Limited independent reviews; new-vendor execution risk; unclear depth of coverage across edge cases	Pricing opacity and potential price escalation	Can be perceived as less nimble; service quality may vary by team/region (anecdotally in industry)

01Competitive Landscape

Narrative analysis

Direct competitors and differentiators
- Formulary
  - Differentiation is presented as a fund administration approach that uses AI and automation to support workflows and emphasizes data reliability and client service.
- Carta
  - Offers fund management and fund administration with a broader platform strategy and multiple add-ons (tax, valuations, forecasting, KYC, etc.).
- SS&C
  - Competes on breadth, scale, and institutional coverage across accounting, reporting, and investor servicing.
Feature comparison: where Formulary may excel vs lag behind (evidence-limited)
- Potential strengths (to validate)
  - Operational turnaround could be faster if processes are modernized
  - Improved client responsiveness if staffed and organized accordingly
  - A more consolidated system experience versus multi-tool legacy stacks
- Potential gaps
  - Edge-case handling for complex structures
  - Depth of integration ecosystem compared with incumbents
  - Global coverage and specialist teams (tax, regulatory reporting across jurisdictions)
Pricing comparison: value proposition vs alternatives
- Carta and SS&C are typically sales-led and quote-based; buyers report pricing complexity in the market.
- Because Formulary doesn’t publish pricing, buyers should benchmark with competing quotes for similar fund structures and service levels.
Customer testimonials comparing Formulary to competitors
- Public, independent comparisons were not found in accessible sources during this research pass.
Market share and adoption trends
- No independent market share estimates were found in accessible sources for Formulary specifically.
- Industry context: incumbents like SS&C are widely established in fund administration.

	Formulary (vendor website)	Carta Fund Administration	SS&C (Fund Administration)
Starting Price	Not publicly listed (quote-based likely)	Not transparently listed as a simple number; contact sales model with add-ons	Not publicly listed (enterprise/quote-based)
Typical buyers	Asset managers seeking an administration service that emphasizes AI-supported tooling and enhanced data controls	Managers wanting to consolidate within the Carta ecosystem and buy add-ons across fund management	Large and complex managers needing a scaled incumbent with broad coverage and long operating history
Key Strength	Vendor states a focus on data reliability, automation, and client service; these claims require validation	Broad platform footprint; add-on modules across fund operations	Scale, breadth, established processes, global capabilities
Key Weakness	Limited independent reviews; new-vendor execution risk; unclear depth of coverage across edge cases	Pricing opacity and potential price escalation	Can be perceived as less nimble; service quality may vary by team/region (anecdotally in industry)

Formulary

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map